# A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

> **NCT02039076** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 48 (actual)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** avatrombopag

## Key facts

- **NCT ID:** NCT02039076
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039076, "A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02039076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*